Brain Metastases Clinical Trials

77 recruiting

Brain Metastases Trials at a Glance

117 actively recruiting trials for brain metastases are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 2 with 55 trials, with the heaviest enrollment activity in Houston, Boston, and Miami. Lead sponsors running brain metastases studies include M.D. Anderson Cancer Center, Baptist Health South Florida, and Fudan University.

Browse brain metastases trials by phase

Treatments under study

About Brain Metastases Clinical Trials

Looking for clinical trials for Brain Metastases? There are currently 77 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Brain Metastases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Brain Metastases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 117 trials

Recruiting
Phase 2

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

Brain Metastases
Medical College of Wisconsin53 enrolled2 locationsNCT05045950
Recruiting
Not Applicable

Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases

Brain Metastases, Adult
Istituto Clinico Humanitas146 enrolled9 locationsNCT05545007
Recruiting
Phase 1

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Brain Metastases, AdultBrain MetastasesBrain Cancer
Baptist Health South Florida20 enrolled1 locationNCT04689048
Recruiting
Phase 2

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

Brain MetastasesCentral Nervous System Cancer
Washington University School of Medicine104 enrolled1 locationNCT07462507
Recruiting
Phase 2

NTS-WBRT in Brain Metastases

Brain Metastases
Massachusetts General Hospital41 enrolled1 locationNCT05013892
Recruiting
Phase 2

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

Brain Metastases
M.D. Anderson Cancer Center316 enrolled1 locationNCT06649058
Recruiting
Phase 3

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Brain Metastases
Canadian Cancer Trials Group206 enrolled86 locationsNCT03550391
Recruiting
Phase 2

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Brain MetastasesTumor
M.D. Anderson Cancer Center104 enrolled1 locationNCT05064280
Recruiting
Not Applicable

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

Brain Metastases
M.D. Anderson Cancer Center20 enrolled1 locationNCT06015295
Recruiting
Phase 1

A Phase 1/1b Study of IAM1363 in HER2 Cancers

HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 2

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Renal Cell CarcinomaBrain Metastases
M.D. Anderson Cancer Center20 enrolled1 locationNCT05048212
Recruiting
Not Applicable

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Non-small Cell Lung CancerBrain MetastasesEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico74 enrolled1 locationNCT06238882
Recruiting
Phase 3

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Brain MetastasesLung AdenocarcinomaWhole-Brain Radiotherapy+2 more
Sun Yat-sen University220 enrolled3 locationsNCT07481786
Recruiting
Phase 1Phase 2

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Lung CancerNSCLCBrain Metastases
Joshua Palmer56 enrolled3 locationsNCT05987644
Recruiting
Not Applicable

Novel Ga68-PSMA PET/CT-tracer to Differentiate Between Radiation Necrosis and Tumor Progression in Brain Metastases

Brain Metastases From Breast CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)Brain Metastases From Melanoma
The Netherlands Cancer Institute100 enrolled1 locationNCT07511933
Recruiting
Not Applicable

Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

Brain MetastasesPulmonary CancerRadionecrosis
Assistance Publique - Hôpitaux de Paris60 enrolled1 locationNCT05977803
Recruiting
Phase 2

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital74 enrolled1 locationNCT07505173
Recruiting
Phase 1Phase 2

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Metastatic Breast CancerBrain Metastases
Weill Medical College of Cornell University41 enrolled3 locationsNCT03449238
Recruiting
Phase 2

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Brain MetastasesNonsmall Cell Lung Cancer Stage III
Wake Forest University Health Sciences60 enrolled1 locationNCT05692635
Recruiting
Phase 2

Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction

Brain Metastases, AdultBrain Tumor - MetastaticBrain Metastases From Non-small Cell Lung Cancer (NSCLC)+1 more
Ayal A. Aizer, MD60 enrolled1 locationNCT07132190